Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsArizona Complete Health Motegrity Coverage | OpenP…
    Ask Trek AI about this page
    CurrentArizona Complete HealthPolicy AZ.CP.PMN.194

    Clinical Policy: Prucalopride (Motegrity)

    Customize your policy alerts

    Sign up for Arizona Complete Health Policy AZ.CP.PMN.194 alerts

    Get alerted when Policy AZ.CP.PMN.194 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Prior authorization and medical-necessity coverage for prucalopride (Motegrity) in Arizona Medicaid, primarily for chronic idiopathic constipation in adults.

    Policy Summary
    PayerArizona Complete Health
    PolicyClinical Policy: Prucalopride (Motegrity)
    Policy CodePolicy AZ.CP.PMN.194
    Change TypeAdministrative clarificationno material clinical or coverage changes
    Effective DateSep 1, 2019
    Last ReviewOct 1, 2020
    Next Review DateN/A
    Key ActionSubmit clinical documentation supporting all applicable approval criteria for prior authorization.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    Adults with CICFDA-approved indication
    7 criteriaInitial approval requirements
    2 mg/dayMaximum covered dose
    12 monthsApproval duration

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Not authorized
    Unaddressed non-FDA-approved indications

    Coverage Criteria

    Initial therapy — chronic idiopathic constipation

    Covered for chronic idiopathic constipation when all of the following are met.

    Initial approval for chronic idiopathic constipation

    • Diagnosis and age: Member has a diagnosis of chronic idiopathic constipation and is at least 18 years old.Age ≥ 18 years
    • Bulk-forming laxative trial: Member has failed one bulk-forming laxative, such as psyllium, unless all are contraindicated or clinically significant adverse effects are experienced.
    • Stimulant laxative trial: Member has failed one stimulant laxative, such as bisacodyl or senna, unless all are contraindicated or clinically significant adverse effects are experienced.
    • Polyethylene glycol trial: Member has failed polyethylene glycol (MiraLax) at up to maximally indicated doses, unless contraindicated or clinically significant adverse effects are experienced.Up to maximally indicated doses
    • Prescription alternative trials: Member has failed Amitiza and Linzess, unless contraindicated or clinically significant adverse effects are experienced.

      Prior authorization may be required for Amitiza and Linzess.

    • Dose limit: Requested dose does not exceed 2 mg (1 tablet) per day.≤ 2 mg/day

    Initial therapy — other diagnoses or indications

    For other diagnoses or indications, follow the applicable off-label policy when the diagnosis is not specifically listed as unauthorized.

    Other diagnoses or indications: Refer to AZ.CP.PMN.53 for Arizona Medicaid if the diagnosis is not specifically listed under Section III as an indication for which coverage is not authorized.

    Continuation therapy — chronic idiopathic constipation

    Continued therapy for chronic idiopathic constipation must meet all of the following.

    Continuation for chronic idiopathic constipation

    • Existing coverage or prior approval: Member is currently receiving the medication through a Centene benefit or previously met the initial approval criteria.
    • Positive response: Member is responding positively to therapy.
    • Dose increase limit: If the request is for a dose increase, the new dose does not exceed 2 mg (1 tablet) per day.≤ 2 mg/day

    Continuation therapy — other diagnoses or indications

    Continued therapy for other diagnoses or indications must meet one of the stated pathways.

    Continuation for other diagnoses or indications

    • Existing use with positive response: Member is currently receiving the medication through a Centene benefit and documentation supports a positive response to therapy.

      Approval duration is the duration of the request or 12 months, whichever is less.

    • Off-label policy referral: Refer to AZ.CP.PMN.53 for Arizona Medicaid if the diagnosis is not specifically listed under Section III as an indication for which coverage is not authorized.

    Non-FDA-approved indications that are not addressed by this policy are excluded from coverage unless sufficient documentation of efficacy and safety supports coverage under the applicable off-label use policy, AZ.CP.PMN.53, for Arizona Medicaid.

    Prucalopride is excluded when the member has hypersensitivity; intestinal perforation or obstruction due to a structural or functional disorder of the gut wall; obstructive ileus; severe inflammatory intestinal conditions such as Crohn disease or ulcerative colitis; or toxic megacolon or megarectum.

    Dose and Eligibility Parameters

    Maximum prucalopride dose
    Maximum dose2 mg (1 tablet) per day
    Minimum age
    Minimum age18 years or older
    Renal impairment dose
    Dose for CrCl below 30 mL/min1 mg PO once daily

    Authorization and Documentation Requirements

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required. Submit clinical documentation supporting all applicable approval criteria. Initial approval is for 12 months; continuation approval is also for 12 months unless otherwise specified.

    • For other diagnoses/indications, approval is for the requested duration or 12 months, whichever is less.
    • The requested dose must not exceed 2 mg (1 tablet) per day.
    Step Therapy

    Alternative-Drug Authorization

    Amitiza (lubiprostone) and Linzess (linaclotide) may also require prior authorization. Document failure, contraindication, or clinically significant adverse effects for each when applicable.

    • Amitiza: chronic idiopathic constipation dose listed as 24 mcg by mouth twice daily; maximum 48 mcg/day.
    • Linzess: chronic idiopathic constipation dose listed as 72–145 mcg by mouth once daily; maximum 145 mcg/day.

    Drug and Indication Overview

    Prucalopride (Motegrity) is a serotonin-4 (5-HT4) receptor agonist. This policy addresses its FDA-approved use for the treatment of chronic idiopathic constipation in adults.

    Key Terms

    Definition
    5-HT4Serotonin-4 receptor agonist
    Definition
    CICChronic idiopathic constipation
    Definition
    FDAFood and Drug Administration

    Initial Therapy

    Initial therapy — chronic idiopathic constipation

    Initial approval for chronic idiopathic constipation requires all listed criteria.

    Motegrity initial therapy

    • Diagnosis and age: Diagnosis of chronic idiopathic constipation and age at least 18 years.Age ≥ 18 years
    • Required laxative and prescription alternatives: Failure of one bulk-forming laxative, one stimulant laxative, polyethylene glycol at up to maximally indicated doses, Amitiza, and Linzess, unless the relevant therapy is contraindicated or causes clinically significant adverse effects.
    • Dose limit: Requested dose does not exceed 2 mg (1 tablet) per day.≤ 2 mg/day

    Continuation Therapy

    Continuation therapy

    Chronic idiopathic constipation continuation therapy must meet all criteria.

    CIC continuation

    • Existing coverage or prior approval: Member is currently receiving the medication through a Centene benefit or previously met the initial approval criteria.
    • Positive response: Member is responding positively to therapy.
    • Dose increase limit: If the request is for a dose increase, the new dose does not exceed 2 mg (1 tablet) per day.≤ 2 mg/day

    Continuation for other diagnoses

    Required Alternative Therapy Trials

    OrderRequired alternative therapyTrial requirement
    1Bulk-forming laxative (for example, psyllium)Failure, unless all are contraindicated or clinically significant adverse effects are experienced.
    2Stimulant laxative (for example, bisacodyl or senna)Failure, unless all are contraindicated or clinically significant adverse effects are experienced.
    3Polyethylene glycol (MiraLax)Failure at up to maximally indicated doses, unless contraindicated or clinically significant adverse effects are experienced.
    4Amitiza (lubiprostone)Failure, unless contraindicated or clinically significant adverse effects are experienced.
    5Linzess (linaclotide)Failure, unless contraindicated or clinically significant adverse effects are experienced.

    Motegrity Quantity Limit

    Motegrity (prucalopride)
    Maximum quantity2 mg (1 tablet) per day
    Policy Summary
    PayerArizona Complete Health
    PolicyClinical Policy: Prucalopride (Motegrity)
    Policy CodePolicy AZ.CP.PMN.194
    Change TypeAdministrative clarificationno material clinical or coverage changes
    Effective DateSep 1, 2019
    Last ReviewOct 1, 2020
    Next Review DateN/A
    Key ActionSubmit clinical documentation supporting all applicable approval criteria for prior authorization.
    SourceLink
    On This Page
    Coverage CriteriaDose and Eligibility ParametersAuthorization and Documentation RequirementsDrug and Indication OverviewKey TermsInitial TherapyContinuation TherapyRequired Alternative Therapy TrialsMotegrity Quantity Limit
    Step Therapy

    Required Constipation Therapy Trials

    For chronic idiopathic constipation, document failure of the required therapies unless all applicable agents are contraindicated or caused clinically significant adverse effects.

    • One bulk-forming laxative, such as psyllium (Metamucil), unless contraindicated or associated with clinically significant adverse effects. Other listed bulk-forming alternatives include calcium polycarbophil (FiberCon) and methylcellulose (Citrucel).
    • One stimulant laxative, such as bisacodyl or senna, unless contraindicated or associated with clinically significant adverse effects.
    • Polyethylene glycol (MiraLAX) at up to maximally indicated doses, unless contraindicated or associated with clinically significant adverse effects. The listed maximum is 34 grams per day.
    • Amitiza and Linzess, unless contraindicated or associated with clinically significant adverse effects.
    Documentation Required

    Clinical Documentation Required

    Submit office chart notes, laboratory results, or other clinical information supporting that the member has met all applicable approval criteria.

    • Documentation must support the diagnosis, age, treatment history, contraindications, clinically significant adverse effects, dose, and response as applicable to the request.
    Documentation Required

    Initial Request Support

    For an initial request for chronic idiopathic constipation, submit documentation supporting all applicable criteria.

    • Diagnosis of chronic idiopathic constipation.
    • Member is age 18 years or older.
    • Failure of the required bulk-forming laxative, stimulant laxative, polyethylene glycol, Amitiza, and Linzess therapies, unless contraindicated or associated with clinically significant adverse effects.
    • The requested dose does not exceed 2 mg (1 tablet) per day.
    Documentation Required

    Continuation Documentation

    For continuation requests, document current use or prior qualification and a positive response to therapy. If requesting a dose increase, the new dose must not exceed 2 mg (1 tablet) per day.

    • The member is currently receiving the medication through the Centene benefit or previously met the initial approval criteria.
    • Documentation supports that the member is responding positively to therapy.
    • For other diagnoses or indications, document current Centene benefit coverage with positive response, or follow the applicable off-label use policy when the diagnosis is not specifically listed as excluded.
    Denial Risk

    Initial Criteria Not Met

    The initial request may be denied when the member does not meet the applicable diagnosis, age, therapy-trial, dosing, or other approval requirements.

    • Diagnosis is not chronic idiopathic constipation and no applicable criterion for another covered indication is satisfied.
    • Member is younger than 18 years.
    • Required constipation therapies have not failed and are not documented as contraindicated or associated with clinically significant adverse effects.
    • Requested dose exceeds 2 mg (1 tablet) per day.
    • Required clinical documentation is not submitted or does not support all applicable criteria.
    Denial Risk

    Unaddressed Non-FDA-Approved Indication

    Non-FDA-approved indications not addressed in this policy are not authorized unless sufficient documentation of efficacy and safety is provided under the applicable off-label use policy.

    • For Arizona Medicaid, refer to off-label use policy AZ.CP.PMN.53 when the diagnosis is not specifically listed under the policy's non-authorized indications.
    Denial Risk

    Contraindication Present

    Authorization is denied or excluded when a listed contraindication is present. Review the member's history and document that none of these contraindications applies before requesting therapy.

    • Hypersensitivity.
    • Intestinal perforation or obstruction due to a structural or functional disorder of the gut wall.
    • Obstructive ileus.
    • Severe inflammatory disease of the intestinal tract, including Crohn's disease, ulcerative colitis, or toxic megacolon/megarectum.
    • No boxed warnings were reported in the policy.

    Other-diagnosis continuation therapy follows one of the policy pathways.

    Other-diagnosis continuation

    • Existing use with positive response: Member is currently receiving the medication through a Centene benefit and documentation supports a positive response to therapy.
    • Off-label policy referral: Refer to AZ.CP.PMN.53 for Arizona Medicaid if the diagnosis is not specifically listed under Section III as an indication for which coverage is not authorized.